Printer Friendly

IGI ANNOUNCES AWARDS OF TWO NEW UNITED STATES PATENTS

 BUENA, N.J., Nov. 22 /PRNewswire/ -- IGI, Inc. (AMEX: IG) today announced the award of two new patents based upon its NovasomeR technologies to one of its subsidiaries. The United States Patent Office has issued Patent Number 5,260,065 entitled "BLENDED LIPID VESICLES." United States Patents issued to IGI and its subsidiaries now total 28.
 BLENDED LIPID VESICLES
 This patent describes a new method of making NovasomeR lipid vesicles using primary or major non-phospholipid structural lipids (particularly those which are useful in cosmetics, pharmaceuticals or dermatologicals) which will not form vesicles in an unblended state. It complements another, recently issued patent entitled HYBRID LIPID VESICLES which uses NovasomesR incorporating phospholipids and glycolipids along with other non-phospholipid NovasomeR components.
 The Company believes such blended lipid vesicles may be useful themselves as virucides and as delivery vehicles for delivery of materials into cells. Based on laboratory tests, the delivered material may include pharmaceutical agents, biological molecules such as enzymes, and even genetic material. The in vitro transfer of enzymes and genes has been shown by demonstration of new enzyme activity and gene expression in target cells following delivery.
 Separately, many cosmetics and dermatologics include compounds which have the function of providing "feel" and other desirable characteristics. Blended NovasomeR vesicles are particularly important in making cosmetically acceptable and stable preparations of water- immiscible material such as retinoic acid, its derivatives, and anthralin. They may also be used to encapsulate such water-immiscible materials as water-insoluble vitamins and anti-oxidants such as vitamin E, flavor oils and anticancer drugs such as levamisole.
 LIPID VESICLE CONTAINING WATER-IN-OIL EMULSIONS
 Most emulsions used in the cosmetics and other industries are oil droplets in a continuous water phase. These preparations generally use detergent-based emulsifiers which may contribute to irritation and chapping and water loss from the skin. This patent describes a method of making an emulsion of water droplets (containing intact NovasomeR lipid vesicles) in a continuous oil phase. The Company believes that such water-in-oil emulsions would be particularly suited to applications such as sun screens; which would resist washing off, and would keep a continuous supple of active sunscreen in contact with the skin. Other applications for which laboratory work is being conducted include use in "pour-on" insecticides for large animals to keep encapsulated oil soluble insecticides in contact with the skin.
 This patent supplements another recently issued HYBRID LIPID VESICLE patent which uses NovasomesR incorporating small amounts of phospholipids and/or glycolipids along with other vesicle components for uses such as transportation of vesicles through membranes or permeation of the skin. The company believes that hybrid vesicles such as these are well suited to solving the problems of skin delivery and cross- membrane transport of both oil soluble and water soluble materials.
 IGI is a diversified company engaged in the development, production and marketing of animal care products, cosmetics, consumer products and human pharmaceuticals.
 -0- 11/22/93
 /CONTACT: Michael Dodge of IGI, Inc., 609-697-1441, or Steven Bruce or Rick Stockton of Abernathy MacGregor Scanlon, 212-371-5999/
 (IG)


CO: IGI, Inc. ST: New Jersey IN: MTC HOU SU:

MP -- NY026 -- 6723 11/22/93 09:51 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 22, 1993
Words:519
Previous Article:LSI LOGIC, ZENITH FORM CHIP ALLIANCEFOR DIGITAL CABLE TRANSMISSION SYSTEM
Next Article:WHEELING-PITTSBURGH CORPORATION ISSUES ANNOUNCEMENT
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters